LAUSR

This study assessed the effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis vulgaris in a real‐world setting. A total of 120 patients (35.8% women; mean age 49.8 years) were enrolled. Mean PASI significantly decreased from 12.0 ± 6.6 at baseline to 4.7 ± 3.2 and 2.3 ± 4.0 at 3 and 12 months, respectively (P < .001). Patients with two or more lines of prior biological therapies had poorer persistence to therapy at 12 months (71%) vs those who were bio‐naïve (93%) or patients with only one prior failure with a biological agent (88%) (log‐rank = 9.33; P = .009). Multivariate regression analysis showed that patients beyond the second line of treatment had an increased risk of discontinuing secukinumab (HR: 3.6; 95% CI 1.3‐10.2), while those without comorbidities had a lower risk (HR: 0.31; 95% CI 0.1‐0.8). Our study confirms the effectiveness and safety of secukinumab in a real‐life setting for psoriatic disease.